J Robert Dorkin
Overview
Explore the profile of J Robert Dorkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
4334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smekalova E, Martinez M, Combe E, Kumar A, Dejene S, Leboeuf D, et al.
Mol Ther Nucleic Acids
. 2024 Jan;
35(1):102112.
PMID: 38292874
Chronic hepatitis B virus (HBV) infection remains a global health problem due to the lack of treatments that prevent viral rebound from HBV covalently closed circular (ccc)DNA. In addition, HBV...
2.
Kauffman K, Oberli M, Dorkin J, Hurtado J, Kaczmarek J, Bhadani S, et al.
Mol Ther Nucleic Acids
. 2018 Mar;
10:55-63.
PMID: 29499956
mRNA therapeutics hold promise for the treatment of diseases requiring intracellular protein expression and for use in genome editing systems, but mRNA must transfect the desired tissue and cell type...
3.
Oberli M, Reichmuth A, Dorkin J, Mitchell M, Fenton O, Jaklenec A, et al.
Nano Lett
. 2017 Mar;
17(3):1326-1335.
PMID: 28273716
The induction of a strong cytotoxic T cell response is an important prerequisite for successful immunotherapy against many viral diseases and tumors. Nucleotide vaccines, including mRNA vaccines with their intracellular...
4.
Fenton O, Kauffman K, McClellan R, Appel E, Dorkin J, Tibbitt M, et al.
Adv Mater
. 2016 Feb;
28(15):2939-43.
PMID: 26889757
Thousands of human diseases could be treated by selectively controlling the expression of specific proteins in vivo. A new series of alkenyl amino alcohol (AAA) ionizable lipid nanoparticles (LNPs) capable...
5.
Dong Y, Dorkin J, Wang W, Chang P, Webber M, Tang B, et al.
Nano Lett
. 2016 Jan;
16(2):842-8.
PMID: 26727632
Safe and effective delivery is required for siRNA and mRNA-based therapeutics to reach their potential. Here, we report on the development of poly(glycoamidoamine) brush nanoparticles as delivery vehicles for siRNA...
6.
Kauffman K, Dorkin J, Yang J, Heartlein M, DeRosa F, Mir F, et al.
Nano Lett
. 2015 Oct;
15(11):7300-6.
PMID: 26469188
Intracellular delivery of messenger RNA (mRNA) has the potential to induce protein production for many therapeutic applications. Although lipid nanoparticles have shown considerable promise for the delivery of small interfering...
7.
Yin H, Kanasty R, Eltoukhy A, Vegas A, Dorkin J, Anderson D
Nat Rev Genet
. 2014 Jul;
15(8):541-55.
PMID: 25022906
Gene-based therapy is the intentional modulation of gene expression in specific cells to treat pathological conditions. This modulation is accomplished by introducing exogenous nucleic acids such as DNA, mRNA, small...
8.
Whitehead K, Dorkin J, Vegas A, Chang P, Veiseh O, Matthews J, et al.
Nat Commun
. 2014 Jun;
5:4277.
PMID: 24969323
One of the most significant challenges in the development of clinically viable delivery systems for RNA interference therapeutics is to understand how molecular structures influence delivery efficacy. Here, we have...
9.
Dong Y, Eltoukhy A, Alabi C, Khan O, Veiseh O, Dorkin J, et al.
Adv Healthc Mater
. 2014 Mar;
3(9):1392-7.
PMID: 24623658
New lipid-like nanomaterials are developed to simultaneously regulate expression of multiple genes. Self-assembled nanoparticles are capable of efficiently encapsulating pDNA and siRNA. These nanoparticles are shown to induce simultaneous gene...
10.
Dong Y, Love K, Dorkin J, Sirirungruang S, Zhang Y, Chen D, et al.
Proc Natl Acad Sci U S A
. 2014 Feb;
111(11):3955-60.
PMID: 24516150
siRNA therapeutics have promise for the treatment of a wide range of genetic disorders. Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA carriers with a wide...